丰原药业(000153) - 2025 Q2 - 季度财报

Financial Performance - The company's operating revenue for the reporting period was CNY 2,027,143,954.81, a decrease of 12.16% compared to CNY 2,307,876,468.11 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 76,278,476.53, down 23.88% from CNY 100,212,492.64 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 60,526,212.25, a decline of 29.32% compared to CNY 85,638,373.28 in the same period last year[21]. - The net cash flow from operating activities was CNY 28,142,889.92, which is 13.44% lower than CNY 32,511,792.92 in the previous year[21]. - Operating profit was 88.6749 million yuan, down 34.18% year-on-year[28]. - Total profit amounted to 88.4324 million yuan, reflecting a decline of 34.76% from the previous year[28]. - The basic earnings per share decreased to CNY 0.1641, down 23.89% from CNY 0.2156 in the same period last year[21]. - The weighted average return on net assets was 3.71%, down from 5.16% in the previous year, a decrease of 1.45%[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,840,465,039.70, reflecting a 3.01% increase from CNY 4,698,947,415.21 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 3.70% to CNY 2,094,240,186.77 from CNY 2,019,573,061.58 at the end of the previous year[21]. - The company's inventory decreased by 1.10% to ¥557,536,183.56, compared to ¥593,108,354.64 at the end of the previous year[45]. - The accounts receivable increased by 22.42% to ¥1,085,026,202.64, compared to ¥934,569,467.81 at the end of the previous year[45]. - Total liabilities increased to ¥2,721,039,273.97 from ¥2,653,036,981.33, representing a growth of about 2.6%[115]. - Current liabilities totaled ¥2,225,277,676.04, up from ¥2,188,094,915.89, marking an increase of approximately 1.9%[115]. Cash Flow - The company reported a significant increase in net cash flow from financing activities, which rose by 186.56% to ¥68,186,034.34, compared to ¥23,794,892.37 in the previous year[39]. - The net cash flow from operating activities decreased by 13.44% to ¥28,142,889.92, down from ¥32,511,792.92 in the previous year[39]. - The net cash flow from investing activities was -¥33,323,198.72, an improvement from -¥55,417,869.60 in the first half of 2024[128]. - Cash inflow from financing activities was ¥514,219,828.53, slightly lower than ¥523,853,270.24 in the previous year[128]. Research and Development - Research and development expenses increased by 21.37% to ¥31,993,776.84, compared to ¥26,360,784.48 in the previous year[39]. - The company focuses on new drug research and development, holding multiple national first and second-class new drug varieties and several proprietary intellectual property products[29]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The total number of common stock shareholders at the end of the reporting period is 34,308[103]. - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.80% of shares, totaling 50,178,992 shares[103]. Corporate Governance and Compliance - The semi-annual financial report has not been audited[78]. - There were no penalties or rectification situations reported during the period[80]. - The company has not reported any major events related to its subsidiaries during the reporting period[97]. - There are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[76]. Market and Operational Risks - The company emphasizes the high risks associated with new drug development, which may impact the recovery of investments and expected benefits if new drug registrations are not approved[6]. - The company is facing risks related to pharmaceutical policy changes, which may impact market competition and future development[60]. - The company has invested in a venture capital fund, which may face long investment recovery periods and risks of underperformance due to market conditions[60]. Environmental and Social Responsibility - The company plans to enhance its environmental protection measures to comply with increasing regulatory requirements and reduce operational risks[61]. - The company has included 7 subsidiaries in the list of enterprises required to disclose environmental information legally[72]. Financial Reporting and Accounting Policies - The company adheres to the accounting standards and principles set forth by the relevant regulations, ensuring accurate financial reporting[151]. - The company uses RMB as its functional currency for financial reporting[154]. - The company has established specific thresholds for recognizing significant bad debt provisions and other financial activities, with amounts exceeding RMB 500,000 for receivables and RMB 5 million for investment activities being considered significant[155].